Lixte exchanges 2,700 Series C preferred for 700K common shares and 20% of Liora subsidiary

LIXTE BIOTECHNOLOGY HOLDINGS, INC.

Orbit Capital Inc. exchanged 2,700 Series C Preferred shares for 700,000 Lixte common shares and 200 ordinary shares of Liora (20% of Liora).
Upon closing, all Series C Preferred shares were cancelled and no longer outstanding.
Lixte retained 800 ordinary shares of Liora after the exchange.
Transaction was exempt from registration under Section 4(a)(2) and Regulation D.

item 1.01item 3.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.